A review of six bioactive compounds from preclinical studies as potential breast cancer inhibitors

Area of Science:

• Oncology
• Pharmacology
• Natural Products Chemistry

Background:

• Breast cancer remains a leading cause of mortality in women globally.
• Current treatments like chemotherapy and radiotherapy have limitations including adverse effects and drug resistance.
• Natural compounds offer a promising alternative due to their medicinal value and availability.

Purpose of the Study:

• To review the anti-breast cancer mechanisms of six natural compounds: cinnamaldehyde, diosmin, taxifolin, phloretin, arctigenin, and eugenol.
• To consolidate evidence from in vitro and in vivo studies on their therapeutic potential.
• To highlight the promise of these natural compounds for future breast cancer drug development.

Main Methods:

• Literature review of preclinical studies (in vitro and in vivo).
• Analysis of the mechanisms of action of selected natural compounds against breast cancer.
• Focus on compounds including cinnamaldehyde, diosmin, taxifolin, phloretin, arctigenin, and eugenol.

Main Results:

• The reviewed natural compounds demonstrated significant breast cancer inhibition.
• Mechanisms include promotion of apoptosis and cell cycle arrest.
• Inhibition of metastasis and invasion, and reduction in tumor growth were observed.

Conclusions:

• Preclinical evidence supports the use of these natural compounds as potential breast cancer therapeutics.
• Cinnamaldehyde, diosmin, taxifolin, phloretin, arctigenin, and eugenol show significant anti-cancer activity.
• These compounds represent promising candidates for developing novel, safe, and effective breast cancer drugs.